Breakthrough in Pretreated EGFR-Mutated NSCLC

DZD6008 Demonstrates Salvage Potential in EGFR C797X–Mutant NSCLC

June 2, 2026

FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

June 1, 2026

Introduction and Frontline Regimen Selection in EGFR-Mutant NSCLC

May 11, 2026

Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS Surveillance

May 11, 2026